Ignite Creation Date:
2024-05-06 @ 7:40 PM
Last Modification Date:
2024-10-26 @ 3:11 PM
Study NCT ID:
NCT06099314
Status:
RECRUITING
Last Update Posted:
2023-10-25
First Post:
2023-10-17
Brief Title:
Fruquintinib in the Cross-line Treatment of Refractory mCRC
Sponsor:
Wuhan Union Hospital China
Organization:
Wuhan Union Hospital China
Study Overview
Official Title:
A Real-world Study of Fruquintinib in the Cross-line Treatment of Refractory mCRC
Status:
RECRUITING
Status Verified Date:
2023-10
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a real-world study Patients with metastatic colorectal cancer who have progressed PD after third-line treatment with fruquintinib combined with PD-1 inhibitors will receive fruquintinib combined with TAS-102 as fourth-line therapy The objective of this study was to observe the efficacy and safety of cross-linefrom third to fourth linetreatment with fruquinitinib
Detailed Description:
This is a real-world study Patients with metastatic colorectal cancer confirmed by histopathology had previously received 2-line system therapy with fluorouracil oxaliplatin irinotecan anti-VEGF anti-EGFR RAS and BRAF wild type treatment with anti-VEGF-TKI is not allowed and had received fruquinitinib combined with PD-1 inhibitors for third-line treatment After progression PD confirmed by RECIST 11 fruquinitinib combined with TAS-102 as fourth-line therapy was received The primary endpoint was observation the overall survival OS of fourth-line treatment of mCRC with fruquinitinib and TAS-102 The study objective is to explore the possibility of cross-line rechallenge of fruquinitinib
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
False
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None